fluticasone propionate + Comparator: Placebo to fluticasone + Comparator: Lipopolysaccharide (LPS) + Comparator: albuterol
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Airway Inflammation
Conditions
Airway Inflammation
Trial Timeline
Mar 1, 2009 → Sep 1, 2009
NCT ID
NCT00869596About fluticasone propionate + Comparator: Placebo to fluticasone + Comparator: Lipopolysaccharide (LPS) + Comparator: albuterol
fluticasone propionate + Comparator: Placebo to fluticasone + Comparator: Lipopolysaccharide (LPS) + Comparator: albuterol is a phase 1 stage product being developed by Merck for Airway Inflammation. The current trial status is completed. This product is registered under clinical trial identifier NCT00869596. Target conditions include Airway Inflammation.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00869596 | Phase 1 | Completed |
Competing Products
6 competing products in Airway Inflammation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| fospropofol + fospropofol + fospropofol + fospropofol | Eisai | Pre-clinical | 23 |
| Levalbuterol HCl Inhalation Solution + Levalbuterol HCl Inhalation Solution + Albuterol HCl Inhalation Solution | Sumitomo Pharma | Phase 3 | 77 |
| Formoterol/Budesonide + lactose | AstraZeneca | Phase 2 | 52 |
| Tiotropium 'Respimat' 5 mcg + Aclidinium Bromide/Formoterol Fumarate 340/12 mcg | AstraZeneca | Approved | 85 |
| Sevoflurane + Desflurane + Rocuronium + Neostigmine + Glycopyrrolate | Baxter | Approved | 82 |
| Desloratadine + Placebo | Organon | Approved | 80 |